BCL2 Fusion Cancer Therapies | Cancer Search

{name}

{subtitle}

loncastuximab tesirine

biomarker

BCL2 Fusion, +2 more biomarkers

condition

Diffuse Large B-Cell Lymphoma

disease state

Relapse/refractory

therapeutic contexts

Subsequent line

drug

loncastuximab tesirine

drug type

chemotherapy, +1 more type

rituximab + polatuzumab vedotin + bendamustine

biomarker

BCL2 Fusion, +2 more biomarkers

condition

Diffuse Large B-Cell Lymphoma

disease state

Relapse/refractory

therapeutic contexts

Subsequent line

drug

bendamustine, +2 more drugs

drug type

chemotherapy, +2 more types

2 Items
Page 1 of 1